AdriaenssensE, DumontL, LottinS, et al. (1998) H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. Am J Pathol, 153:1597-1607.
2.
BenetatosL, VartholomatosG, HatzimichaelE (2011) MEG3 imprinted gene contribution in tumorigenesis. Int J Cancer, 129:773-779.
3.
BerteauxN, LottinS, MonteD, et al. (2005) H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem, 280:29625-29636.
4.
BraconiC, KogureT, ValeriN, et al. (2011) microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular Cancer. Oncogene, 30:4750-4756.
5.
CaoX, ZhuangS, HuY, et al. (2016) Associations between polymorphisms of long non-coding RNA MEG3 and risk of colorectal cancer in Chinese. Oncotarget, 7:19054-19059.
6.
CuiH, OnyangoP, BrandenburgS, et al. (2002) Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res, 62:6442-6446.
7.
GaboryA, JammesH, DandoloL (2010) The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays, 32:473-480.
8.
GaboryA, RipocheMA, YoshimizuT, DandoloL (2006) The H19 gene: regulation and function of a non-coding RNA. Cytogenet Genome Res, 113:188-193.
9.
GaoT, HeB, PanY, et al. (2014) H19 DMR methylation correlates to the progression of esophageal squamous cell carcinoma through IGF2 imprinting pathway. Clin Transl Oncol, 16:410-417.
10.
GaoW, ZhuM, WangH, et al. (2015) Association of polymorphism in long non-coding RNA H19 with coronary artery disease risk in a Chinese population. Mutat Res, 772:15-22.
11.
GhaediH, ZareA, OmraniMD, et al. (2018) Genetic variants in long noncoding RNA H19 and MEG3 confer risk of type 2 diabetes in an Iranian population. Gene, 675:265-271.
12.
HibiK, NakamuraH, HiraiA, et al. (1996) Loss of H19 imprinting in esophageal cancer. Cancer Res, 56:480-482.
13.
KeniryA, OxleyD, MonnierP, et al. (2012) The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol, 14:659-665.
14.
LuoM, LiZ, WangW, et al. (2013) Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett, 333:213-221.
15.
MaC, NongK, ZhuH, et al. (2014) H19 promotes pancreatic cancer metastasis by derepressing let-7′s suppression on its target HMGA2-mediated EMT. Tumour Biol, 35:9163-9169.
16.
MatoukIJ, HalleD, RavehE, et al. (2016) The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision. Oncotarget, 7:3748-3765.
17.
PanJX (2017) LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway. Eur Rev Med Pharmacol Sci, 21:322-328.
18.
RachmilewitzJ, GoshenR, ArielI, et al. (1992) Parental imprinting of the human H19 gene. FEBS Lett, 309:25-28.
19.
ThorvaldsenJL, DuranKL, BartolomeiMS (1998) Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev, 12:3693-3702.
20.
TsangWP, NgEK, NgSS, et al. (2010) Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis, 31:350-358.
21.
WangP, RenZ, SunP (2012) Overexpression of the long non-coding RNA MEG3 impairs in vitro glioma cell proliferation. J Cell Biochem, 113:1868-1874.
22.
XiaT, LiaoQ, JiangX, et al. (2014) Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep, 4:6088.
23.
YanJ, GuoX, XiaJ, et al. (2014) MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1. Med Oncol, 31:879.
24.
YangC, TangR, MaX, et al. (2015) Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the Chinese Han population. Oncotarget, 6:15311-15320.
25.
YingL, HuangY, ChenH, et al. (2013) Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Mol Biosyst, 9:407-411.
26.
ZhuoH, TangJ, LinZ, et al. (2016) The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma. Mol Carcinog, 55:209-219.
